Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.

The introduction of enzalutamide and abiraterone has led to improvement in the treatment of metastatic castration-resistant prostate cancer. However, acquired resistance to enzalutamide and abiraterone therapies frequently develops within a short period in many patients. In the present study, we developed enzalutamide-resistant prostate cancer cells in an effort to understand the mechanisms of resistance. Global gene-expression analysis showed that the steroid biosynthesis pathway is activated in enzalutamide-resistant prostate cancer cells. One of the crucial steroidogenic enzymes, AKR1C3, was significantly elevated in enzalutamide-resistant cells. In addition, AKR1C3 is highly expressed in metastatic and recurrent prostate cancer and in enzalutamide-resistant prostate xenograft tumors. LC/MS analysis of the steroid metabolites revealed that androgen precursors such as cholesterol, DHEA and progesterone, as well as androgens are highly upregulated in enzalutamide-resistant prostate cancer cells compared to the parental cells. Knockdown of AKR1C3 expression by shRNA or inhibition of AKR1C3 enzymatic activity by indomethacin resensitized enzalutamide-resistant prostate cancer cells to enzalutamide treatment both in vitro and in vivo. In contrast, overexpression of AKR1C3 confers resistance to enzalutamide. Furthermore, the combination of indomethacin and enzalutamide resulted in significant inhibition of enzalutamide-resistant tumor growth. These results suggest that AKR1C3 activation is a critical resistance mechanism associated with enzalutamide resistance; targeting intracrine androgens and AKR1C3 will overcome enzalutamide resistance and improve survival of advanced prostate cancer patients.

[1]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[2]  A. Gao,et al.  Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. , 2014, Endocrine-related cancer.

[3]  N. Sharifi,et al.  Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences , 2014, British Journal of Cancer.

[4]  H. Kwan,et al.  Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin. , 2014, The Journal of investigative dermatology.

[5]  I. Haviv,et al.  Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer , 2014, Clinical Cancer Research.

[6]  Yezi Zhu,et al.  Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[7]  H. Kung,et al.  Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model , 2014, Oncogene.

[8]  S. Conzen,et al.  Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer , 2014, Hormones and Cancer.

[9]  Yezi Zhu,et al.  Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells , 2014, The Prostate.

[10]  D. Zheng,et al.  Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.

[11]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[12]  Joshua M. Korn,et al.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.

[13]  S. Taneja,et al.  Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The Journal of urology.

[14]  Duane D. Miller,et al.  Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth , 2013, Clinical Cancer Research.

[15]  P. Nelson,et al.  A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer , 2013, Cell.

[16]  Yezi Zhu,et al.  Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer , 2013, Molecular Cancer Therapeutics.

[17]  C. Evans,et al.  NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants , 2013, Molecular Cancer Therapeutics.

[18]  N. Gaikwad.  Ultra performance liquid chromatography-tandem mass spectrometry method for profiling of steroid metabolome in human tissue. , 2013, Analytical chemistry.

[19]  T. Kawasaki,et al.  Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer , 2013, Scientific Reports.

[20]  L. Marnett,et al.  Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer , 2013, Journal of medicinal chemistry.

[21]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[22]  C. Sander,et al.  Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. , 2012, Cancer research.

[23]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[24]  Andrew P. Turnbull,et al.  Crystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3 , 2012, PloS one.

[25]  P. Nelson,et al.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.

[26]  Chiara Fracassi,et al.  The non-steroidal anti-inflammatory drug indomethacin activates the eIF2α kinase PKR, causing a translational block in human colorectal cancer cells. , 2012, The Biochemical journal.

[27]  P. Nelson,et al.  Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. , 2011, Cancer research.

[28]  P. Nelson,et al.  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.

[29]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[30]  D. Tsavachidou,et al.  MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: Apreliminary report. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  K. Tomer,et al.  Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. , 2011, Cancer research.

[32]  Yezi Zhu,et al.  Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. , 2011, Genes & cancer.

[33]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[34]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[35]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[36]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[37]  T. Kodama,et al.  Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer , 2007, Journal of Clinical Pathology.

[38]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[39]  D. Peehl,et al.  Identification of the Major Oxidative 3α-Hydroxysteroid Dehydrogenase in Human Prostate That Converts 5α-Androstane-3α,17β-diol to 5α-Dihydrotestosterone: A Potential Therapeutic Target for Androgen-Dependent Disease , 2006 .

[40]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Fernand Labrie,et al.  The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology , 1997, Steroids.

[42]  W. E. Gye,et al.  CANCER RESEARCH , 1923, British medical journal.

[43]  P. Troncoso,et al.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. , 2015, European urology.

[44]  D. Peehl,et al.  Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. , 2006, Molecular endocrinology.

[45]  J. Simard,et al.  The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. , 1997, Steroids.

[46]  F. Hinman,et al.  EUROPEAN UROLOGY. , 1928, California and western medicine.